Recruiting

Observational Study

Sponsor:

University of Cincinnati

Code:

NCT03288233

Conditions

Diabetes Mellitus

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Breath carbon monoxide measurement

Study Details

Brief summary:

Hemoglobin A1C (HbA1c) is the cornerstone of blood sugar monitoring. As HbA1c is formed by the covalent reaction of glucose with hemoglobin throughout the lifespan of the red blood cell (RBC), it is used as a surrogate marker for integrated mean blood glucose over time. The HbA1c value therefore is dependent on the average amount of time the RBC spends in the circulation (mean RBC age or MRBC). However, our previous studies measuring red cell lifespan using either an age cohort label (ex vivo labeling with biotin) or a population label (stable isotope) have demonstrated, contrary to established dogma, that the MRBC varies substantially among individuals and is sufficiently variable to affect HA1c interpretation in a significant percentage of individuals with diabetes. Although the stable isotope method is suitable for clinical studies, it has limited potential for application to large population of subjects. A potential alternative to the stable isotope approach that could be applied routinely to the average patient in the clinic is measurement of exhaled carbon monoxide (eCO) concentration, a reflection of RBC heme turnover. In general, the primary advantage of applying exhaled breath analyses to human clinical diagnostics and therapeutic monitoring is that this technique is noninvasive, safe, simple, and provides near-real time measurements. The purpose of this observational study is to optimize the collection of eCO in a normal control population followed by measurement in a cohort of subjects previously assessed by either the SI or biotin methods for comparison.

Conditions

Diabetes Mellitus

Healthy

Study ID

NCT03288233

Start date

Apr, 2015

Status verified date

Sep, 2017

Completion date

Aug, 2018

Anticipated

Primary completion date

May, 2018

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Subjects will be between age 18 and 75 years, non-pregnant, with a goal of equal gender and race (Caucasian vs. African-American) distribution

Exclusion Criteria:

  • known hemoglobinopathy or RBC disorder
  • positive pregnancy test (in women of child-bearing potential or are breast feeding or planning pregnancy during the course of the study;
  • baseline serum creatinine >1.5 mg/dl
  • CBC outside the normal range
  • history of GI blood loss or coagulopathy
  • urine microalbumin >100 mcg/mg creatinine (spot collection);
  • transaminases >3 X the upper limit of normal
  • presence of serum antibodies to biotinylated proteins (which could interfere with the biotin RBC labeling protocol)
  • greater than or equal to NYHA stage 3 heart failure;
  • active infection;
  • known rheumatologic disease
  • uncontrolled hypo-or hyperthyroidism or an underlying illness known to be associated with either body wasting or changes in serum proteins
  • lung transplantation, irradiation, recent surgery, recent intensive care admission, asthma, COPD, cystic fibrosis, smoking, recent hematoma, uncontrolled hypo- or hyperthyroidism or an underlying illness known to be associated with either body wasting or changes in serum proteins (e.g. certain malignancies including multiple myeloma or tuberculosis).

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Primary Group

Interventions

Breath carbon monoxide measurement

Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.

Primary outcome measure

  • Average end expiratory alveolar concentration of Carbon monoxide (ppm) in morning before breakfast [ Time Frame: four consecutive weeks ]
  • Average end expiratory alveolar concentration of CO (ppm) in morning 30 min after breakfast [ Time Frame: four consecutive weeks ]
  • Average end expiratory alveolar concentration of CO (ppm) 30 min after lunch [ Time Frame: one day sampling ]
  • Average end expiratory alveolar concentration of CO (ppm) 5 hours after lunch [ Time Frame: one day sampling ]

Central Contacts and Locations

Central contacts

Locations

University of Cincinnati

Recruiting

Cincinnati, Ohio, United States, 45220

Contacts

Principal Investigator:

Robert Cohen, MD

More Information

Sponsor

University of Cincinnati

Last update posted

Sep 20, 2017

Last verified

Sep, 2017

Keywords

  • Hemoglobin A1c
  • HbA1c
  • End tidal carbon monoxide

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Cincinnati on 2017-09-20.